Skip to main content

Novel organometallic anticancer compounds

Objective

Currently the most widely used drugs for the treatment of cancer are platinum compounds, used in nearly 50% of all chemotherapeutic regimens. However the platinums can suffer from problems of resistance, a limited spectrum of activity, and side-effects. Hence new agents with new mechanisms of action are urgently needed. We have discovered novel organometallic osmium and iridium compounds with more potent anticancer activity and unique mechanisms of action. Initial work on an osmium compound has demonstrated promising activity against colorectal cancer without toxic side-effects, providing an opportunity to satisfy unmet clinical needs.
The ERC PoC funding will allow the discovery phase to be advanced, to turn hits into leads by establishing and validating target sites, and elucidating mechanisms of action. The techniques employed to achieve this PoC will combine high throughput proteomcs/genomics approaches with image analysis of cancer cell morphology in a mathematical analysis to determine the mechanism of action. Data from cancer models will validate the efficacy of the most active compounds. This portfolio of data, together with desk research on potential patient populations, will provide a strong basis for attracting a partner in the next stage of preclinical development.

Call for proposal

ERC-2012-PoC
See other projects for this call

Host institution

THE UNIVERSITY OF WARWICK
Address
Kirby Corner Road - University House
CV4 8UW Coventry
United Kingdom
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 149 559
Administrative Contact
Peter Hedges (Dr.)

Beneficiaries (1)

THE UNIVERSITY OF WARWICK
United Kingdom
EU contribution
€ 149 559
Address
Kirby Corner Road - University House
CV4 8UW Coventry
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Peter Hedges (Dr.)